{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T12:51:21Z","timestamp":1778071881031,"version":"3.51.4"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T00:00:00Z","timestamp":1691107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Purpose:<\/jats:bold> To systematically assess the efficacy and safety of sacubitril\/valsartan (SV) by comparison with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) for the treatment of heart failure caused by acute myocardial infarction (HF-AMI) based on current randomized controlled trials (RCTs).<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Several electronic databases were searched up to 27 May 2023. Primary endpoints were the efficacy including the left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), N-terminal pro-B type natriuretic peptide (NT-proBNP) and 6-min walk test (6MWT) and secondary endpoints were the safety including the major adverse cardiovascular event (MACE) and adverse reaction (AE).<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 14 RCTs were included and all patients were from China. Among included 1,991 patients, 997 patients received SVs and 994 patients received ACEIs\/ARBs. The pooled results demonstrated that patients in the SV group showed significantly better efficacy representing as increased LVEF [weighted mean difference (WMD): 4.43%, 95% confidence interval (CI): 2.84%\u20136.02%, <jats:italic>p<\/jats:italic> &amp;lt; 0.001] and 6MWT (WMD: 30.84\u00a0m, 95% CI: 25.65\u00a0m\u201336.03\u00a0m, <jats:italic>p<\/jats:italic> &amp;lt; 0.001) and decreased LVEDD (WMD: \u22123.24\u00a0mm, 95% CI: \u22124.96\u00a0mm \u223c -1.52\u00a0mm, <jats:italic>p<\/jats:italic> &amp;lt; 0.001) and NT-proBNP (WMD: \u2212188.12\u00a0pg\/mL, 95% CI: \u2212246.75\u00a0pg\/mL \u223c 129.49\u00a0pg\/mL, <jats:italic>p<\/jats:italic> &amp;lt; 0.001), which was also verified by subgroup analysis based on the history of percutaneous coronary intervention (PCI). Besides, the SV group showed significantly lower incidence rate of MACE [relative risk (RR): 0.60, 95% CI: 0.47\u20130.75, <jats:italic>p<\/jats:italic> &amp;lt; 0.001] and patients receiving SVs in the non-PCI group also showed lower incidence of AE (RR: 0.38, 95% CI: 0.20\u20130.71, <jats:italic>p<\/jats:italic> = 0.002).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> For the treatment of HF-AMI, SV is more effective and safer than ACEI\/ARB based on current evidence, but more high-quality RCTs are still needed to verify above findings.<\/jats:p>","DOI":"10.3389\/fphar.2023.1237210","type":"journal-article","created":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T09:54:59Z","timestamp":1691142899000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["The efficacy and safety of sacubitril\/valsartan compared with ACEI\/ARB in the treatment of heart failure following acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.3389","volume":"14","author":[{"given":"Jinquan","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengzhuo","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shisu","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1002\/ehf2.14097","article-title":"Sacubitril\/valsartan in heart failure: Efficacy and safety in and outside clinical trials","volume":"9","author":"Abdin","year":"2022","journal-title":"Esc. Heart Fail"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1002\/ejhf.2663","article-title":"Sacubitril\/valsartan versus ramipril for patients with acute myocardial infarction: Win-ratio analysis of the PARADISE-MI trial","volume":"24","author":"Berwanger","year":"2022","journal-title":"Eur. J. Heart Fail"},{"key":"B4","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/s0197-2456(01)00147-7","article-title":"Quality in the reporting of randomized trials in surgery: Is the Jadad scale reliable?","volume":"22","author":"Bhandari","year":"2001","journal-title":"Control Clin. Trials"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1002\/ejhf.2572","article-title":"Sacubitril\/valsartan use patterns among older adults with heart failure in clinical practice: A population-based cohort study of >25 000 medicare beneficiaries","volume":"24","author":"Bhatt","year":"2022","journal-title":"Eur. J. Heart Fail"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.3969\/j.issn.1000-3614.2020.12.002","article-title":"Expert consensus on the prevention and treatment of heart failure after myocardial infarction","volume":"35","year":"2020","journal-title":"Chin. Circulation J."},{"key":"B7","first-page":"157","article-title":"Clinical observation of Shakubactrivalsartan in the treatment of acute myocardial infarction patients with heart failure","volume":"41","author":"Cao","year":"2020","journal-title":"J. Med. Forum"},{"key":"B8","doi-asserted-by":"publisher","first-page":"4481","DOI":"10.26355\/eurrev_202305_32454","article-title":"The usability of MCP-1, fetuin-A, TAS, and TOS levels in the diagnosis of acute myocardial infarction","volume":"27","author":"Ciftci","year":"2023","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/s0197-2456(99)00026-4","article-title":"Assessing the quality of randomized trials: Reliability of the Jadad scale","volume":"20","author":"Clark","year":"1999","journal-title":"Control Clin. Trials"},{"key":"B10","volume-title":"Analysis of the efficacy of sacubitril\/valsartan in acute myocardial infarction patients with cardiac insufficiency undergoing PCI","author":"Cui","year":"2021"},{"key":"B11","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1161\/CIRCULATIONAHA.121.054892","article-title":"Effect of neprilysin inhibition on left ventricular remodeling in patients with asymptomatic left ventricular systolic dysfunction late after myocardial infarction","volume":"144","author":"Docherty","year":"2021","journal-title":"Circulation"},{"key":"B12","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jchf.2020.06.020","article-title":"Sacubitril\/Valsartan: Neprilysin inhibition 5 Years after PARADIGM-HF","volume":"8","author":"Docherty","year":"2020","journal-title":"JACC Heart Fail"},{"key":"B13","volume-title":"The safety and efficacy of sacubitril\/valsartan in patients with acute anterior wall ST-segment elevation myocardial infarction after PCI Nanchang Unviersity","author":"Dong","year":"2021"},{"key":"B14","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"Bmj"},{"key":"B15","doi-asserted-by":"publisher","first-page":"792885","DOI":"10.3389\/fcvm.2022.792885","article-title":"Therapeutic peptides to treat myocardial ischemia-reperfusion injury","volume":"9","author":"Fernandez Rico","year":"2022","journal-title":"Front. Cardiovasc Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1080\/15548627.2022.2115675","article-title":"NPPA\/atrial natriuretic peptide is an extracellular modulator of autophagy in the heart","volume":"19","author":"Forte","year":"2023","journal-title":"Autophagy"},{"key":"B17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.13847\/j.cnki.lnmu.2022.02.013","article-title":"Clinical observation of sacubitril valsartan sodiumfor HFrEF patients after STEMI percutaneous coronary intervention","volume":"43","author":"Fu","year":"2022","journal-title":"J. Jinzhou Med. Univ."},{"key":"B18","volume-title":"Effects of sacubitril\/valsartan on ventricular remodeling in patents with left ventricular systolic dysfunction following acute anterior wall myocardial infarction","author":"Haiyan","year":"2021"},{"key":"B19","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.ijcha.2019.02.005","article-title":"Sacubitril\/valsartan averts post-myocardial infarction ventricular remodeling and preserves heart function","volume":"22","author":"Hajra","year":"2019","journal-title":"Int. J. Cardiol. Heart Vasc."},{"key":"B20","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1136\/heartjnl-2018-313752","article-title":"Education level and outcomes after acute myocardial infarction in China","volume":"105","author":"Huo","year":"2019","journal-title":"Heart"},{"key":"B21","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/ehf2.13144","article-title":"Heart failure after myocardial infarction: Incidence and predictors","volume":"8","author":"Jen\u010da","year":"2021","journal-title":"Esc. Heart Fail"},{"key":"B22","doi-asserted-by":"publisher","first-page":"118","DOI":"10.14163\/j.cnki.11-5547\/r.2021.15.043","article-title":"Analysis of the efficacy of Shakubactrivalsartan in the treatment of heart failure after myocardial infarction","volume":"16","author":"Jiang","year":"2021","journal-title":"China Prac. Med."},{"key":"B23","first-page":"83","article-title":"Effect analysis of sakobactri valsartan on PCI for patients with acute myocardial infarction complicated with cardiac dysfunction","volume":"44","author":"Jiao","year":"2023","journal-title":"J. Med. Forum"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/ejhf.1532","article-title":"Sacubitril\/valsartan eligibility and outcomes in the ESC-EORP-HFA heart failure long-term registry: Bridging between European medicines agency\/food and drug administration label, the PARADIGM-HF trial, ESC guidelines, and real world","volume":"21","author":"Kapelios","year":"2019","journal-title":"Eur. J. Heart Fail"},{"key":"B25","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11886-018-0944-4","article-title":"The sacubitril\/valsartan, a first-in-class, angiotensin receptor neprilysin inhibitor (ARNI): Potential uses in hypertension, heart failure, and beyond","volume":"20","author":"Kario","year":"2018","journal-title":"Curr. Cardiol. Rep."},{"key":"B26","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1001\/jamacardio.2021.0122","article-title":"Use of machine learning models to predict death after acute myocardial infarction","volume":"6","author":"Khera","year":"2021","journal-title":"JAMA Cardiol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/s0140-6736(14)60921-1","article-title":"ST-Segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-retrospective acute myocardial infarction study): A retrospective analysis of hospital data","volume":"385","author":"Li","year":"2015","journal-title":"Lancet"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1177\/1060028015593093","article-title":"Dual angiotensin receptor and neprilysin inhibition with sacubitril\/valsartan in chronic systolic heart failure: Understanding the new PARADIGM","volume":"49","author":"Lillyblad","year":"2015","journal-title":"Ann. Pharmacother."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.16440\/j.cnki.1674-8166.2021.12.13","article-title":"Effect of Shakubactriovalsartan sodium combined with recombinant human brain natriuretic peptide on patients with heart failure after acute myocardial infarction","volume":"22","author":"Liu","year":"2021","journal-title":"Chronic Pathematology J."},{"key":"B30","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ejps.2018.11.037","article-title":"Sacubitril\/valsartan (LCZ696) significantly reduces aldosterone and increases cGMP circulating levels in a canine model of RAAS activation","volume":"128","author":"Mochel","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jchf.2021.09.007","article-title":"Early B-type natriuretic peptide change in HFrEF patients treated with sacubitril\/valsartan: A pooled analysis of EVALUATE-HF and PROVE-HF","volume":"10","author":"Myhre","year":"2022","journal-title":"JACC Heart Fail"},{"key":"B32","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"B33","doi-asserted-by":"publisher","first-page":"754499","DOI":"10.3389\/fcvm.2021.754499","article-title":"Sacubitril-valsartan, clinical benefits and related mechanisms of action in heart failure with reduced ejection fraction. A review","volume":"8","author":"Pascual-Figal","year":"2021","journal-title":"Front. Cardiovasc Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s00018-023-04777-w","article-title":"Atrial natriuretic peptide stimulates autophagy\/mitophagy and improves mitochondrial function in chronic heart failure","volume":"80","author":"Raffa","year":"2023","journal-title":"Cell Mol. Life Sci."},{"key":"B35","volume-title":"Effect of entresto on heart failure after emergency PCI in AMI patients and its effect on lp-PLA2","author":"Sheng","year":"2022"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e15987","DOI":"10.1097\/md.0000000000015987","article-title":"The trim-and-fill method for publication bias: Practical guidelines and recommendations based on a large database of meta-analyses","volume":"98","author":"Shi","year":"2019","journal-title":"Med. Baltim."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1136\/heartjnl-2017-311295","article-title":"Sacubitril\/valsartan: Beyond natriuretic peptides","volume":"103","author":"Singh","year":"2017","journal-title":"Heart"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.36740\/WLek202207124","article-title":"Prevalence, clinical and functional characteristics of patients with acute myocardial infarction complicated by acute heart failure","volume":"75","author":"Solomonchuk","year":"2022","journal-title":"Wiad. Lek."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1093\/eurheartj\/ehad348","article-title":"Lower income, higher risk: Disparities in treatments and outcomes of patients with acute myocardial infarction","volume":"44","author":"Vergallo","year":"2023","journal-title":"Eur. Heart J."},{"key":"B40","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1093\/eurheartj\/ehac759","article-title":"Endocrine functions of the heart: From bench to bedside","volume":"44","author":"Volpe","year":"2023","journal-title":"Eur. Heart J."},{"key":"B41","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1002\/ehf2.12694","article-title":"Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: Design and rationale of the PARALLAX trial","volume":"7","author":"Wachter","year":"2020","journal-title":"Esc. Heart Fail"},{"key":"B42","doi-asserted-by":"publisher","first-page":"7650937","DOI":"10.1155\/2022\/7650937","article-title":"Effect of entresto on clinical symptoms, ventricular remodeling, rehabilitation, and hospitalization rate in patients with both acute myocardial infarction and acute heart failure","volume":"2022","author":"Wang","year":"2022","journal-title":"Evidence-based Complementary Altern. Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/MCA.0000000000000932","article-title":"Effects of Sacubitril\/Valsartan on cardiac function in patients with acute anterior wall ST-segment elevation myocardial infarction after PCI with reduced ejection fraction","volume":"41","author":"Wang","year":"2020","journal-title":"J. Hebei Med. Univ."},{"key":"B44","doi-asserted-by":"publisher","first-page":"97","DOI":"10.14164\/j.cnki.cn11-5581\/r.2022.05.035","article-title":"Analysis of the clinical efficacy of sacubitril and valsartan on patients with severe heart failure after acute myocardial infarction","volume":"16","author":"Xie","year":"2022","journal-title":"Chin. J. Mod. Drug Appl."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/s41440-021-00706-1","article-title":"Angiotensin receptor-neprilysin inhibitors: Comprehensive review and implications in hypertension treatment","volume":"44","author":"Yamamoto","year":"2021","journal-title":"Hypertens. Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1136\/heartjnl-2020-318306","article-title":"Sex differences in heart failure hospitalisation risk following acute myocardial infarction","volume":"107","author":"Yandrapalli","year":"2021","journal-title":"Heart"},{"key":"B47","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1093\/ehjqcco\/qcab019","article-title":"Utilization of sacubitril\/valsartan in patients with heart failure with reduced ejection fraction: Real-world data from the ARIADNE registry","volume":"8","author":"Zeymer","year":"2022","journal-title":"Eur. Heart J. Qual. Care Clin. Outcomes"},{"key":"B48","doi-asserted-by":"publisher","first-page":"11","DOI":"10.13638\/j.issn.1671-4040.2020.14.005","article-title":"Observation of HFrEF after PCI in the treatment of senile STEMI with Shakuba triqu and valsartan","volume":"20","author":"Zhao","year":"2020","journal-title":"Pract. Clin. J. Integr. Traditional Chin. West. Med."},{"key":"B49","volume-title":"Efficacy and safety of sacubitril valsartan in the treatment of heart failure with preserved ejection fraction after emergency PCI for STEMI Hubei University of Medicine","author":"Zhou","year":"2022"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1237210\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T09:55:21Z","timestamp":1691142921000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1237210\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,4]]},"references-count":49,"alternative-id":["10.3389\/fphar.2023.1237210"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1237210","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,4]]},"article-number":"1237210"}}